News
MARKET UPDATE-8th MAR 2023
In Australian news this week, the Reserve Bank of Australia decided to raise its monetary policy rate for the 10th consecutive meeting. The increase of 0.25 percentage points took the official rate to...
MARKET UPDATE-8th MAR 2023
In Australian news this week, the Reserve Bank of Australia decided to raise its monetary policy rate for the 10th consecutive meeting. The increase of 0.25 percentage points took the official rate to...
MARKET UPDATE-1st Mar 2023
In economic news this week, the Australian Bureau of Statistics published the Wages Price Index for the December quarter of 2022. Wages were said to have risen by 0.8 per cent...
MARKET UPDATE-1st Mar 2023
In economic news this week, the Australian Bureau of Statistics published the Wages Price Index for the December quarter of 2022. Wages were said to have risen by 0.8 per cent...
Revealing the 10 biggest smart city funding dea...
Stoic investee Morse Micro’s US$95 million Series A funding round has been named on the GlobalData Plc’s ‘biggest smart city deals of 2022’!
Revealing the 10 biggest smart city funding dea...
Stoic investee Morse Micro’s US$95 million Series A funding round has been named on the GlobalData Plc’s ‘biggest smart city deals of 2022’!
MARKET UPDATE-22TH FEB 2023
In Australian banking news, as part of the corporate earnings season, Westpac has revealed that 45 per cent of its home loans were made with a ‘serviceability buffer’ that assumed an interest...
MARKET UPDATE-22TH FEB 2023
In Australian banking news, as part of the corporate earnings season, Westpac has revealed that 45 per cent of its home loans were made with a ‘serviceability buffer’ that assumed an interest...
Certa Therapeutics releases ground breaking Pha...
Portfolio company Certa has released results of the Phase 2 clinical trial of its novel therapy for Scleroderma (an inflammatory skin thickening condition that can also affect a range of internal organs).
Certa Therapeutics releases ground breaking Pha...
Portfolio company Certa has released results of the Phase 2 clinical trial of its novel therapy for Scleroderma (an inflammatory skin thickening condition that can also affect a range of internal organs).
Stoic VC leads $1m Pre-Series A for Lenexa Medical
We’re pleased to be leading Lenexa’s pre-series A, a team bridging geriatric care with the future of preventative medicine.
Stoic VC leads $1m Pre-Series A for Lenexa Medical
We’re pleased to be leading Lenexa’s pre-series A, a team bridging geriatric care with the future of preventative medicine.